HUMACYTE INC Share Price Today: Live Updates & Key Insights

HUMACYTE INC share price today is $0.8105, up -8.34%. The stock opened at $0.90505 against the previous close of $0.8541, with an intraday high of $0.90505 and low of $0.701.

HUMACYTE INC Share Price Chart

HUMACYTE INC

us-stock
To Invest in {{usstockname}}
us-stock

HUMACYTE INC Share Price Performance

$0.8105 -0.0834(-8.34%) HUMA at 23 Mar 2026 01:31 PM Biotechnology
Lowest Today 0.701
Highest Today 0.90505
Today’s Open 0.90505
Prev. Close 0.8541
52 Week High 3.36
52 Week Low 0.70
Day’s Range: Low 0.701 High 0.90505
52-Week Range: Low 0.70 High 3.36
1 day return -
1 Week return -31.56
1 month return -32.46
3 month return -28.04
6 month return -56.5
1 year return -76.74
3 year return -74.5
5 year return -93.77
10 year return -

HUMACYTE INC Institutional Holdings

BlackRock Inc 5.13

Vanguard Group Inc 4.36

Vanguard Total Stock Mkt Idx Inv 2.74

iShares Russell 2000 ETF 1.97

Geode Capital Management, LLC 1.93

Millennium Management LLC 1.36

State Street Corp 1.25

Morgan Stanley - Brokerage Accounts 1.09

UBS Group AG 1.04

Woodline Partners LP 1.04

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Citadel Advisors Llc 0.81

Fidelity Small Cap Index 0.79

Two Sigma Investments LLC 0.77

Charles Schwab Investment Management Inc 0.64

iShares Biotechnology ETF 0.62

BNP Paribas Arbitrage, SA 0.57

Northern Trust Corp 0.53

Susquehanna International Group, LLP 0.52

iShares Russell 2000 Value ETF 0.51

State St Russell Sm/Mid Cp® Indx SL Cl I 0.50

LPL Financial Corp 0.43

Fidelity Extended Market Index 0.42

Schwab US Small-Cap ETF™ 0.38

Vanguard Russell 2000 ETF 0.38

Private Advisor Group, LLC 0.29

Jane Street Group LLC 0.27

Royal Bank of Canada 0.26

The Goldman Sachs Group Inc 0.25

Marshall Wace Asset Management Ltd 0.25

Vanguard Health Care ETF 0.25

State St Russell Sm Cap® Indx SL Cl I 0.23

iShares Micro-Cap ETF 0.21

Schwab Small Cap Index 0.20

NT R2000 Index Fund - NL 0.18

Blackrock Extended Mkt Fund CF 0.17

Fidelity Total Market Index 0.14

Extended Equity Market Fund K 0.14

NT R2000 Index Fund - DC - NL - 3 0.14

iShares Russell 2000 Growth ETF 0.14

HUMACYTE INC Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

HUMACYTE INC Fundamentals

Market Cap 151.10 M

PB Ratio 57.7713

PE Ratio 0.0

Enterprise Value 161.43 M

Total Assets 137.87 M

Volume 31558370

HUMACYTE INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:6187000 6.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-49000 -0.0M, FY20:null 0.0M, FY19:6187000 6.2M

Annual Net worth FY23:-89390000 -89.4M, FY22:64219000 64.2M, FY21:37536000 37.5M, FY20:-68726000 -68.7M, FY19:null 0.0M

Quarterly Revenue Q3/2025:753000 0.8M, Q2/2025:301000 0.3M, Q1/2025:517000 0.5M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:493000 0.5M, Q2/2025:-1772000 -1.8M, Q1/2025:-1462000 -1.5M, Q3/2024:null 0.0M, Q2/2024:-1823000 -1.8M

Quarterly Net worth Q3/2025:-17510000 -17.5M, Q2/2025:-37658000 -37.7M, Q1/2025:39139000 39.1M, Q3/2024:-39202000 -39.2M, Q2/2024:-56663000 -56.7M

About HUMACYTE INC & investment objective

Company Information Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Organisation Biotechnology

Employees 218

Industry Biotechnology

CEO Dr. Laura E. Niklason M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

HUMACYTE INC FAQs

What is the share price of HUMACYTE INC today?

The current share price of HUMACYTE INC is $0.8105.

Can I buy HUMACYTE INC shares in India?

Yes, Indian investors can buy HUMACYTE INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy HUMACYTE INC shares in India?

You can easily invest in HUMACYTE INC shares from India by:

Can I buy fractional shares of HUMACYTE INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of HUMACYTE INC?

HUMACYTE INC has a market cap of $151.10 M.

In which sector does HUMACYTE INC belong?

HUMACYTE INC operates in the Biotechnology sector.

What documents are required to invest in HUMACYTE INC stocks?

To invest, you typically need:

What is the PE and PB ratio of HUMACYTE INC?

The PE ratio of HUMACYTE INC is N/A and the PB ratio is 57.77.